These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37813015)

  • 1. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
    Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
    Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
    Riudavets M; Sullivan I; Abdayem P; Planchard D
    ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Deruxtecan in
    Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
    N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus for HER2 alterations testing in non-small-cell lung cancer.
    Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
    ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Genomic Features of
    Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
    JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic
    Yun KM; Bazhenova L
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
    Zhang S; Wang W; Xu C; Zhang Y; Cai X; Wang Q; Song Z; Li Z; Yu J; Zhong W; Wang Z; Liu J; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Dong X; Pang F; Wang K; Yao C; Lin G; Li S; Yang Z; Luo J; Jia H; Nie X; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Xia Y; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Gao W; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Yu G; Shi L; Xia Y; Gao F; Zhang X; Xu T; Zhou W; Wang H; Liu Z; Yang N; Wu L; Wang Q; Wang G; Hong Z; Wang J; Fang M; Fang Y; Zhang Y; Song Y; Ma S; Fang W; Lu Y
    Thorac Cancer; 2023 Jan; 14(1):91-104. PubMed ID: 36444143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting
    Liu S; Li S; Hai J; Wang X; Chen T; Quinn MM; Gao P; Zhang Y; Ji H; Cross DAE; Wong KK
    Clin Cancer Res; 2018 Jun; 24(11):2594-2604. PubMed ID: 29298799
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
    He X; Hou L; Bai J; Sun C; Wang D; An G
    Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
    Takakura T; Yamamoto N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
    Waliany S; Neal JW; Engel-Nitz N; Lam C; Lin F; Park L; Le L; Nagasaka M
    Clin Lung Cancer; 2024 Jun; 25(4):319-328.e1. PubMed ID: 38403548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
    Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
    Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
    Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].
    Ren C; Cao H; Zheng J; Sun W; Zhou J
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):291-302. PubMed ID: 37183644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab in the treatment of non-small cell lung cancer.
    Azzoli CG; Krug LM; Miller VA; Kris MG; Mass R
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):59-65. PubMed ID: 11894015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
    Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
    Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.